Promoted Content Promoted Content

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Novartis Pharmaceuticals Corporation

    Client Virtual Booth

    NOVARTIS PHARMACEUTICALS CORPORATION

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Novartis Pharmaceuticals Corporation
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Klybeckstrasse 141, CH-4057, Basel
    Telephone
    Telephone
    +41 61 324 11 11
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.novartis.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Novartis drug cuts recurrence risk by 25% in early-stage breast cancer
    Novartis drug cuts recurrence risk by 25% in early-stage breast cancer

    https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-drug-cuts-recurrence-risk-by-25-early-stage-breast-cancer-2023-06-02/

    REUTERS
    03 Jun 2023
    Share Share
    EU regulator recommends revoking approval for Novartis’ sickle cell disease drug
    EU regulator recommends revoking approval for Novartis’ sickle cell disease drug

    https://www.pharmatimes.com/news/eu_regulator_recommends_revoking_approval_for_novartis_sickle_cell_disease_drug_1492209

    Emily Kimber PHARMATIMES
    30 May 2023
    Share Share
    Novartis Purchases Cystinosis Gene Therapy from AVROBIO
    Novartis Purchases Cystinosis Gene Therapy from AVROBIO

    https://www.pharmtech.com/view/novartis-purchases-cystinosis-gene-therapy-from-avrobio

    Grant Playter PHARMATECH
    30 May 2023
    Share Share
    EMA committee marketing authorisation for Novartis’SCD med, Adakveo
    EMA committee marketing authorisation for Novartis’SCD med, Adakveo

    http://www.pharmabiz.com/NewsDetails.aspx?aid=159412&sid=2

    PHARMIWEB
    29 May 2023
    Share Share
    EU regulator recommends revoking nod for Novartis' sickle-cell drug Adakveo
    EU regulator recommends revoking nod for Novartis' sickle-cell drug Adakveo

    https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-recommends-revoking-authorisation-novartis-adakveo-2023-05-26/

    REUTERS
    27 May 2023
    Share Share
    EMA recommends revoking authorization of Novartis' sickle cell drug
    EMA recommends revoking authorization of Novartis' sickle cell drug

    https://endpts.com/ema-recommends-revoking-authorization-of-novartis-sickle-cell-drug/

    Zachary Brennan ENDPTS
    26 May 2023
    Share Share
    Sandoz Marketing Authorization Applications for denosumab accepted by EMA
    Sandoz Marketing Authorization Applications for denosumab accepted by EMA

    https://www.globenewswire.com/news-release/2023/05/25/2675804/0/en/Sandoz-Marketing-Authorization-Applications-for-proposed-biosimilar-denosumab-accepted-by-EMA.html

    GLOBENEWSWIRE
    25 May 2023
    Share Share
    ASCO: Merck, Novartis to face moment of truth in early cancers
    ASCO: Merck, Novartis to face moment of truth in early cancers

    https://www.fiercepharma.com/pharma/asco-preview-mercks-keytruda-novartis-kisqali-face-moment-truth-early-stage-cancers

    Angus Liu FIERCE PHARMA
    25 May 2023
    Share Share
    Novartis to buy Avrobio gene therapy for $88M, ending M&A rumor
    Novartis to buy Avrobio gene therapy for $88M, ending M&A rumor

    https://www.fiercebiotech.com/biotech/novartis-buy-avrobio-gene-therapy-88m-leaving-rest-biotech-shelf

    Nick Paul Taylor FIERCE BIOTECH
    23 May 2023
    Share Share
    Novartis beefs up gene therapy pipeline, spending $87.5M on an Avrobio therapy
    Novartis beefs up gene therapy pipeline, spending $87.5M on an Avrobio therapy

    https://endpts.com/novartis-beefs-up-gene-therapy-pipeline-spending-87-5m-on-an-avrobio-therapy/

    Kyle LaHucik ENDPTS
    22 May 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2023-05-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search